News | October 28, 2010

Study Shows Cesium-131 Viable for Breast Cancer Treatment

October 28, 2010 – An initial feasibility study has demonstrated the ability to use cesium-131 (Cs-131) brachytherapy seeds in accelerated partial breast irradiation (APBI) for breast cancer treatment. The study looked at IsoRay’s patented therapy for treating early stage, localized breast cancer.

Using a third-party device cleared by the U.S. Food and Drug Administration (FDA), IsoRay conducted several studies to evaluate the Cs-131 internal radiation therapy in APBI treatment. The initial studies showed it to be a viable alternative to high dose rate radiation.

APBI is an emerging radiation treatment used with breast-conserving surgery (lumpectomy) that obtains the highest possible rate of breast cancer control while offering minimal cosmetic impact. It delivers radiation treatment directly around the lumpectomy site, where most cancers are likely to reoccur. Without APBI, women who have a lumpectomy undergo up to six weeks of radiation treatment for the entire affected breast following surgery. A substantial part of the body is exposed to radiation and the breast can be left deformed.

Doctors can vigorously treat a variety of cancers while limiting the damage to healthy surrounding tissues.

"We believe this new application of Cesium-131 will have a significant impact on breast cancer and improve the quality of life for many women who are struggling with this devastating disease,” said Dwight Babcock, CEO of IsoRay. “It is extremely fitting that we are able to reveal this important development during Breast Cancer Awareness Month. I have high expectations for the treatment's availability in 2011.”

With established CMS codes, Cs-131 is FDA-cleared for use in the treatment of cancers throughout the body including breast cancer. More than 100 centers across the country are using it to treat brain, colon, head and neck, lung, ocular melanoma and prostate cancers.

For more information: www.isoray.com

Related Content

DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Aktina’s interchangeable cones are lightweight and extremely accurate
News | Radiation Therapy | August 02, 2017
Aktina Medical announced a collaboration with Philips Medical Systems and Elekta Instruments for SRS interlocking at...
News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
Accuray Receives 510(k) Clearance for iDMS Data Management System
Technology | Oncology Information Management Systems (OIMS) | July 31, 2017
July 31, 2017 — Accuray Inc. announced it has received 510(k) clearance from the U.S.
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Radiotherapy Prior to Surgery Reduces Secondary Tumor Risk in Early-Stage Breast Cancer Patients
News | Radiation Therapy | July 24, 2017
Moffitt Cancer Center researchers launched a first-of-its-kind study comparing the long-term benefits of radiation...
Overlay Init